262 related articles for article (PubMed ID: 25883221)
1. Prognostic value of a 92-probe signature in breast cancer.
Akter S; Choi TG; Nguyen MN; Matondo A; Kim JH; Jo YH; Jo A; Shahid M; Jun DY; Yoo JY; Nguyen NN; Seo SW; Ali L; Lee JS; Yoon KS; Choe W; Kang I; Ha J; Kim J; Kim SS
Oncotarget; 2015 Jun; 6(17):15662-80. PubMed ID: 25883221
[TBL] [Abstract][Full Text] [Related]
2. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
3. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
[TBL] [Abstract][Full Text] [Related]
4. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Mook S; Schmidt MK; Viale G; Pruneri G; Eekhout I; Floore A; Glas AM; Bogaerts J; Cardoso F; Piccart-Gebhart MJ; Rutgers ET; Van't Veer LJ;
Breast Cancer Res Treat; 2009 Jul; 116(2):295-302. PubMed ID: 18661261
[TBL] [Abstract][Full Text] [Related]
5. Validation of 70-gene prognosis signature in node-negative breast cancer.
Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
[TBL] [Abstract][Full Text] [Related]
6. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
[TBL] [Abstract][Full Text] [Related]
7. An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.
Tang J; Cui Q; Zhang D; Liao X; Zhu J; Wu G
J Cell Mol Med; 2019 Aug; 23(8):4980-4990. PubMed ID: 31124293
[TBL] [Abstract][Full Text] [Related]
8. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
9. Population-based molecular prognosis of breast cancer by transcriptional profiling.
Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
[TBL] [Abstract][Full Text] [Related]
10. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
[TBL] [Abstract][Full Text] [Related]
11. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
12. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.
Hanker LC; Rody A; Holtrich U; Pusztai L; Ruckhaeberle E; Liedtke C; Ahr A; Heinrich TM; Sänger N; Becker S; Karn T
Breast Cancer Res Treat; 2013 Jan; 137(2):407-16. PubMed ID: 23242614
[TBL] [Abstract][Full Text] [Related]
13. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
14. The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Cockburn JG; Hallett RM; Gillgrass AE; Dias KN; Whelan T; Levine MN; Hassell JA; Bane A
BMC Cancer; 2016 Jul; 16():555. PubMed ID: 27469239
[TBL] [Abstract][Full Text] [Related]
15. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
16. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
[TBL] [Abstract][Full Text] [Related]
17. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Liu D
Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
[TBL] [Abstract][Full Text] [Related]
18. Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.
Huang CC; Tu SH; Lien HH; Huang CS; Huang CJ; Lai LC; Tsai MH; Chuang EY
Breast Cancer Res Treat; 2014 Sep; 147(2):353-70. PubMed ID: 25158930
[TBL] [Abstract][Full Text] [Related]
19. Model selection for prognostic time-to-event gene signature discovery with applications in early breast cancer data.
Ahdesmäki M; Lancashire L; Proutski V; Wilson C; Davison TS; Harkin DP; Kennedy RD
Stat Appl Genet Mol Biol; 2013 Oct; 12(5):619-35. PubMed ID: 24077567
[TBL] [Abstract][Full Text] [Related]
20. A 16 Yin Yang gene expression ratio signature for ER+/node- breast cancer.
Xu W; Jia G; Cai N; Huang S; Davie JR; Pitz M; Banerji S; Murphy L
Int J Cancer; 2017 Mar; 140(6):1413-1424. PubMed ID: 27925180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
